If they do partner, it won't be just for 3100, it will also be for 3112...JMHO....After all, why would you spend your $$ on the one less likely to be effective against cancer caused by HPV?? Think about it. If Inovio were to retain rights to 3112, how would there be any benefit to a firm partnering on just 3100?
P & F chart still has a target of $$$$$$$$$$ 21.50 per share,
but we all know lots of biotech companies witha market cap of 3 or 4 BILLION, and
they do not have nearly as much promise as Inovio or even a partner like INO has,
much less insiders holding large positions.